Atlas Genetics raises £16.9m for market entry of Chlamydia-diagnostics


Bristol – Atlas Genetics has raised £16.9m from a syndicate of new and existing investors led by Novartis Venture Funds, and Consort Medical plc. The series B round will be drawn down over three years to help to commercialize infectious disease tests, especially the global launch of the Velox diagnostic-kit for Chlamydia and gonorrhea. Commercial launch of the system is planned for 2012. The money will also be used for the development of other infectious disease tests and to expand the immunoassay capability of the Velox system.
Velox is a point of care-diagnostic system for a broad range of infectious diseases using either nucleic acid or immuno-assays. Atals’s CEO John Clarkson commented: “We are delighted to welcome the new investors at this time when the company’s first productn is being transferred to manufacture and the core capabilities of the sensor chemistry are being expanded.“
The new investors in this series B financing are Novartis Venture Funds, LSP (Life Sciences Partners), BB Biotech Ventures and Johnson & Johnson Development Corporation. The newly announced financing follows a £1.5 million round in February 2011 supported by Consort Medical plc and other investors. The Company has been funded previously, and continues to be supported, by YFM Equity Partners, Braveheart Investment Group, Wyvern Asset Management, the Crescent Seedcorn Fund and private investors.



Cambridge – Restoring absent p53 to lung tumour cells in mice can induce mregression in aggressive tumours, but does not have the same effect on early-stage tumours or less malignant cells residing in more advanced tumours. The...



Bristol – British biochemists have unravelled why metastatic prostate cancer cells do not stop migration on contact with non-cancer cells (Nature Cell Biol, DOI: 10.1038/ncb2122). Their findings may lay the foundations for...



Swansea – Probiotic bacteria can reduce the length of diarrhoea and significantly cut the risk of episodes lasting for more than four days. These are the findings of a new systematic review of data from 63 trials involving 8,014...



London – Broker and middle-market investment bank Piper Jaffray has announced it will stop selling securities for European issuers, which means biotech companies will have less access to full-service banks that offer a range of...



British drug delivery company Hospira (Leamington) has named Svend Andersen a Corporate VP and President for Europe, the Middle East and Africa. Under Andersen’s leadership, Hospira is aiming to increase its current market share...



London-based drug developer PepTcell Ltd. (London) has appointed Manfred Scheske as its CEO of Consumer Health. Scheske joins the firm from GlaxoSmithKline, where he worked for 25 years, most recently as President of Consumer...



London - The UK's Technology Strategy Board launched the Stratified Medicines Innovation Platform to provide over L50 million for personalized medicines research over the next five years. The platform will bring together...



Atlanta - The world's first clinical trial of a therapy derived from human embryonic stem cells has started, US-researchers announced on October 11th. A first patient with spinal cord injury was treated at Shepherd Center, a...



At the 10-year anniversary of the Human Genome Project, we stand poised to sequence entire cancer genomes from large numbers of clinical samples and gain an unprecedented insight into the genomic landscape of a wide range of...

Displaying results 71 to 80 out of 396

< Previous 71-80 Next >

© 2007-2015 BIOCOM


Product of the week



All Events

Stock list

All quotes


  • MEDIGENE (D)10.45 EUR7.51%
  • WILEX (D)3.65 EUR5.49%
  • SUMMIT (UK)4.03 GBP3.87%


  • 4SC (D)4.59 EUR-6.33%
  • BAVARIAN NORDIC (D)41.82 EUR-6.28%
  • BIOFRONTERA (D)2.06 EUR-5.50%


  • DBV Technologies (F)52.75 EUR22.8%
  • THERAMETRICS (CH)0.07 CHF16.7%
  • MEDIGENE (D)10.45 EUR16.6%


  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • NORDIC NANOVECTOR (N)25.20 NOK-26.5%
  • TRANSGENE (F)3.68 EUR-26.4%


  • 4SC (D)4.59 EUR345.6%
  • ADOCIA (F)65.40 EUR336.0%
  • WILEX (D)3.65 EUR319.5%


  • CHRONTECH PHARMA (S)0.01 SEK-87.5%
  • ACTIVE BIOTECH (S)8.85 SEK-70.6%
  • NEOVACS (F)1.10 EUR-69.3%

No liability assumed, Date: 04.07.2015

Current issue

All issues